{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:00:03Z","timestamp":1789509603490,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007058","name":"Northern Illinois University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jchromb.2025.124573","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T14:11:18Z","timestamp":1743689478000},"page":"124573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Development and validation of a stability-indicating reversed phase high-performance liquid chromatography method for quantifying rivaroxaban (XARELTO)"],"prefix":"10.1016","volume":"1257","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1478-6310","authenticated-orcid":false,"given":"Aktham","family":"Mestareehi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2025.124573_bb0005","unstructured":"Janssen Pharmaceuticals, I. Xarelto (rivaroxaban) prescription blood thinner, 2011."},{"key":"10.1016\/j.jchromb.2025.124573_bb0010","doi-asserted-by":"crossref","first-page":"14999","DOI":"10.3390\/molecules190914999","article-title":"A novel synthesis of the oxazolidinone antithrombotic agent rivaroxaban","volume":"19","author":"Yuan","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.jchromb.2025.124573_bb0020","unstructured":"FDA, Xarelto approval history (September 1, 2014))."},{"key":"10.1016\/j.jchromb.2025.124573_bb0015","unstructured":"National Center for Biotechnology Information, PubChem Compound Summary for CID 9875401, Rivaroxaban (Nov. 26, 2024)."},{"key":"10.1016\/j.jchromb.2025.124573_bb0025","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","article-title":"New anticoagulants","volume":"3","author":"Weitz","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jchromb.2025.124573_bb0030","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.jchromb.2025.124573_bib63","first-page":"9979234","article-title":"Metformin Increases Protein Phosphatase 2A Activity in Primary Human Skeletal Muscle Cells Derived from Lean Healthy Participants","volume":"2021","author":"Mestareehi","year":"2021","journal-title":"Journal of Diabetes Research"},{"key":"10.1016\/j.jchromb.2025.124573_bb0035","article-title":"A new method development and validation for analysis of rivaroxaban in formulation by RP-HPLC","volume":"1","author":"Sekhar","year":"2012","journal-title":"Res. Desk"},{"key":"10.1016\/j.jchromb.2025.124573_bb0040","doi-asserted-by":"crossref","DOI":"10.1590\/S1984-82502013000200018","article-title":"RP-HPLC method development and validation for estimation of rivaroxaban in pharmaceutical dosage forms","volume":"49","author":"\u00c7elebier","year":"2013","journal-title":"Braz. J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.jchromb.2025.124573_bib61","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.1021\/acsomega.3c07787","article-title":"Impact of Protein Phosphatase Expressions on the Prognosis of Hepatocellular Carcinoma Patients","volume":"9","author":"Mestareehi","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.jchromb.2025.124573_bb0045","unstructured":"(ICH), I. C. o. H. Validation of Analytical Procedures: Methodology (Q2(R1), 2005), ICH guidance for industry, 2005."},{"issue":"24","key":"10.1016\/j.jchromb.2025.124573_bib62","doi-asserted-by":"crossref","first-page":"26075","DOI":"10.1021\/acsomega.4c01496","article-title":"Global Gene Expression Profiling and Bioinformatics Analysis Reveal Downregulated Biomarkers as Potential Indicators for Hepatocellular Carcinoma","volume":"9","author":"Mestareehi","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.jchromb.2025.124573_bb0050","unstructured":"Validation of Chromatographic Methods. N.P: FDA: Center for Drug Evaluation and Research, N. P. N., Linda L."},{"key":"10.1016\/j.jchromb.2025.124573_bb0055","unstructured":"United States pharmacopeia, X., 1990 <1225>."},{"key":"10.1016\/j.jchromb.2025.124573_bb0060","unstructured":"Administration, F. a. D. Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products. (November 2003)."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023225001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:00:16Z","timestamp":1744876816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023225001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":15,"alternative-id":["S1570023225001254"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124573","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a stability-indicating reversed phase high-performance liquid chromatography method for quantifying rivaroxaban (XARELTO)","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"124573"}}